402 related articles for article (PubMed ID: 30220083)
1. VSIG-3 as a ligand of VISTA inhibits human T-cell function.
Wang J; Wu G; Manick B; Hernandez V; Renelt M; Erickson C; Guan J; Singh R; Rollins S; Solorz A; Bi M; Li J; Grabowski D; Dirkx J; Tracy C; Stuart T; Ellinghuysen C; Desmond D; Foster C; Kalabokis V
Immunology; 2019 Jan; 156(1):74-85. PubMed ID: 30220083
[TBL] [Abstract][Full Text] [Related]
2. A small molecule inhibitor of VSIG-8 prevents its binding to VISTA.
Chen W; Qie C; Hu X; Wang L; Jiang J; Liu W; Liu J
Invest New Drugs; 2022 Aug; 40(4):690-699. PubMed ID: 35404016
[TBL] [Abstract][Full Text] [Related]
3. Structural Basis of VSIG3: The Ligand for VISTA.
Xie X; Chen C; Chen W; Jiang J; Wang L; Li T; Sun H; Liu J
Front Immunol; 2021; 12():625808. PubMed ID: 33841409
[TBL] [Abstract][Full Text] [Related]
4. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses.
Wang L; Rubinstein R; Lines JL; Wasiuk A; Ahonen C; Guo Y; Lu LF; Gondek D; Wang Y; Fava RA; Fiser A; Almo S; Noelle RJ
J Exp Med; 2011 Mar; 208(3):577-92. PubMed ID: 21383057
[TBL] [Abstract][Full Text] [Related]
5. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function.
Zhao R; Chinai JM; Buhl S; Scandiuzzi L; Ray A; Jeon H; Ohaegbulam KC; Ghosh K; Zhao A; Scharff MD; Zang X
Proc Natl Acad Sci U S A; 2013 Jun; 110(24):9879-84. PubMed ID: 23716685
[TBL] [Abstract][Full Text] [Related]
6. T Cell Activation Pathways: B7, LFA-3, and ICAM-1 Shape Unique T Cell Profiles.
Wingren AG; Parra E; Varga M; Kalland T; Sjogren HO; Hedlund G; Dohlsten M
Crit Rev Immunol; 2017; 37(2-6):463-481. PubMed ID: 29773030
[TBL] [Abstract][Full Text] [Related]
7. New checkpoints in cancer immunotherapy.
Ni L; Dong C
Immunol Rev; 2017 Mar; 276(1):52-65. PubMed ID: 28258699
[TBL] [Abstract][Full Text] [Related]
8. Dual silencing of tumor-intrinsic VISTA and CTLA-4 stimulates T-cell mediated immune responses and inhibits MCF7 breast cancer development.
Hosseinkhani N; Hemmat N; Baghbani E; Baghbanzadeh A; Kazemi T; Mokhtarzadeh A; Jafarlou M; Amin Doustvandi M; Baradaran B
Gene; 2024 Feb; 896():148043. PubMed ID: 38042220
[TBL] [Abstract][Full Text] [Related]
9. VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy.
Yuan L; Tatineni J; Mahoney KM; Freeman GJ
Trends Immunol; 2021 Mar; 42(3):209-227. PubMed ID: 33495077
[TBL] [Abstract][Full Text] [Related]
10. High-Affinity Anti-VISTA Antibody Protects against Sepsis by Inhibition of T Lymphocyte Apoptosis and Suppression of the Inflammatory Response.
Tao T; Bo L; Li T; Shi L; Zhang H; Ye B; Xu Y; Ma Q; Deng X; Zhang G
Mediators Inflamm; 2021; 2021():6650329. PubMed ID: 34366711
[TBL] [Abstract][Full Text] [Related]
11. VISTA is an immune checkpoint molecule for human T cells.
Lines JL; Pantazi E; Mak J; Sempere LF; Wang L; O'Connell S; Ceeraz S; Suriawinata AA; Yan S; Ernstoff MS; Noelle R
Cancer Res; 2014 Apr; 74(7):1924-32. PubMed ID: 24691993
[TBL] [Abstract][Full Text] [Related]
12. V-Set and immunoglobulin domain containing (VSIG) proteins as emerging immune checkpoint targets for cancer immunotherapy.
Zhou X; Khan S; Huang D; Li L
Front Immunol; 2022; 13():938470. PubMed ID: 36189222
[TBL] [Abstract][Full Text] [Related]
13. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.
Janakiram M; Shah UA; Liu W; Zhao A; Schoenberg MP; Zang X
Immunol Rev; 2017 Mar; 276(1):26-39. PubMed ID: 28258693
[TBL] [Abstract][Full Text] [Related]
14. Targeting the V-Type Immunoglobulin Domain-Containing Suppressor to T Cell Activation (VISTA) with Agonist Monoclonal Antibodies in Autoimmunity.
Jung M; Bonavida B
Crit Rev Immunol; 2022; 42(4):37-49. PubMed ID: 37022358
[TBL] [Abstract][Full Text] [Related]
15. VISTA: A Target to Manage the Innate Cytokine Storm.
ElTanbouly MA; Zhao Y; Schaafsma E; Burns CM; Mabaera R; Cheng C; Noelle RJ
Front Immunol; 2020; 11():595950. PubMed ID: 33643285
[TBL] [Abstract][Full Text] [Related]
16. An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA.
Mehta N; Maddineni S; Kelly RL; Lee RB; Hunter SA; Silberstein JL; Parra Sperberg RA; Miller CL; Rabe A; Labanieh L; Cochran JR
Sci Rep; 2020 Sep; 10(1):15171. PubMed ID: 32938950
[TBL] [Abstract][Full Text] [Related]
17. VISTA expressed in tumour cells regulates T cell function.
Mulati K; Hamanishi J; Matsumura N; Chamoto K; Mise N; Abiko K; Baba T; Yamaguchi K; Horikawa N; Murakami R; Taki M; Budiman K; Zeng X; Hosoe Y; Azuma M; Konishi I; Mandai M
Br J Cancer; 2019 Jan; 120(1):115-127. PubMed ID: 30382166
[TBL] [Abstract][Full Text] [Related]
18. Transcriptome profiling reveals transcriptional regulation of VISTA in T cell activation.
Yuan D; Zhang Y; Liu W; He X; Chen W; Liu L; Yang L; Wang Y; Wu Y; Liu J
Mol Immunol; 2023 May; 157():101-111. PubMed ID: 37004501
[TBL] [Abstract][Full Text] [Related]
19. B7-H7 (HHLA2) inhibits T-cell activation and proliferation in the presence of TCR and CD28 signaling.
Rieder SA; Wang J; White N; Qadri A; Menard C; Stephens G; Karnell JL; Rudd CE; Kolbeck R
Cell Mol Immunol; 2021 Jun; 18(6):1503-1511. PubMed ID: 32005952
[TBL] [Abstract][Full Text] [Related]
20. Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses.
Bennett F; Luxenberg D; Ling V; Wang IM; Marquette K; Lowe D; Khan N; Veldman G; Jacobs KA; Valge-Archer VE; Collins M; Carreno BM
J Immunol; 2003 Jan; 170(2):711-8. PubMed ID: 12517932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]